source
- aTyr Pharma cuts 60% of staff to fund second phase 3 trial of lung disease drug efzofitimodaTyr Pharma announced it will reduce its workforce by about 60%, leaving roughly 20 employees, to reallocate resources toward its lung disease program. The cut follows the company's previous phase…
- Fresenius Kabi recalls Tyenne (tocilizumab-aazg) 400 mg injection vials over glass particle contaminationFresenius Kabi announced a recall of a specific lot of its Tyenne (tocilizumab-aazg) injection, 400 mg/20 mL vials, after detecting glass particles in the product. The company said the contaminati…